|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
March 2004FeaturesEconomics Five Steps to Managing BiologicsAs knowledge of the human genome is turned into useful treatments, health plans and insurers now face the hard part – figuring out how to incorporate these new products into medical and pharmacy benefit plans. Thomas Morrow, MD, offers a framework to help plans tackle this enormous challenge. Regulatory FDA: Change Is GoodThe transfer of oversight of most biologic medications to the FDA’s Center for Drug Evaluation generally garners praise. Will the efficiencies expected to result in the review process ultimately reduce drug-review times and costs? Business Specialty Pharmacy Booms, But For How Long?A growing armamentarium of biotech therapies has given rapid rise to an industry focused on cost-effective drug distribution and delivery. Clinical How Well Are Specialty Injectable Drugs Managed?PharmAnalysis surveyed MCOs to learn how they are managing – or planning to manage – injectable products, and why. Leading Edge Renewing the Assault on mRNARNA interference may lend itself to new treatments for a wide range of diseases. RNA interference resembles two older therapies, antisense and ribozymes, in that the gene-silencing target is messenger RNA. Is RNA interference really the Next Big Thing – or just a variation on an older but still intriguing theme? DepartmentsEditorial Sculpting a new journal
David B. Nash, MD, MBA
Drugs and Diagnostics 2003 Was Stellar for Biotechs; New Applications Make 2004 Promising
Bob Carlson Discourse: Legislative Medicare Bill Draws Both Nods and Yawns from BiotechMedicare bill’s effect? It depends on whom you ask. Biotech Business Biotech Capital Markets Finally Open After Long Drought
Amanda Brower Corporate Spotlight A Place for Biologics in the Managed Care Environment: An Evolving Perspective
Diane Parks and Steven Lo In the Pipeline Biotech Pipelines Brim With Oncology ProductsBiotechs brimming with oncology products but diversifying. |
|||||